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In the last decades, several studies have highlighted the pivotal role of inflammasomes in the 
molecular control of inflammatory processes and the pathological role of NLRP3 
inflammasome has been well established in different pathological settings. The discovery of 
agents able to prevent inflammasome activation is a promising therapeutic strategy to 
decrease chronic inflammation and associated damage. To date, different approaches have 
been pursued, among which reversible or irreversible modification of reactive cysteine 
residues of relevant proteins seems to be the prevalent one. In view of the above, we designed 
a library of electrophilic warheads bearing α,β-unsaturated nitrile and carbonyl-substituents.1 
These compounds were able to significantly prevent NLRP3-dependent pyroptosis of THP-1 
cells. We demonstrated via a thiol trapping kinetic assay and 1H NMR experiments that the 
biological activity of this series of compounds is dependent on their reactivity as Michael 
acceptors. The most promising warheads identified also proved able to directly inhibit the 
NLRP3 ATPase activity of isolated enzyme; unfortunately, these compounds exerted a certain 
degree of cytotoxicity on THP-1 cells, which could be related to their high reactivity. Thus, 
we developed new series of safer compounds by tuning down the reactivity of the 
electrophilic warhead through the chemical modulation of the acrylate scaffold. Thanks to this 
approach, we were able to obtain INF39 (11), a noncytotoxic molecule able to counteract 
NLRP3 activation through direct irreversible interaction with NLRP3 protein.2 We better 
investigated his mechanism of action, and 11 has revealed able to block the conformational 
change required for inflammasome activation (Bioluminescence Resonance Energy Transfer 
experiment on recombinant NLRP3). Our preliminary in vitro ADME studies showed that 
INF39 was stable in simulated gastric and intestinal fluids, and it was absorbed into the 
intestinal epithelium, where it can 
act locally and generate a nontoxic 
active metabolite. On the basis of the 
preliminary ADME profile, INF39 
was selected for in vivo studies in a 
model of DNBS-induced colitis in 
rats. After oral administration, 
INF39 significantly reduced 
systemic and colonic inflammation.  
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